Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics Webcast (2020)

This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting. Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners & Physician Assistants)

Learning Objectives

After completing this activity, participants will be able to:

  1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.
  2. Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients.
  3. Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.
  4. Describe advances in genomic testing and personalized medicine for urologic cancers.
  5. Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
09/09/2020
Course expires: 
09/09/2021
Part of: 
Summer School Webcast Series - CME (2020)
Rating: 
0

Education Council Disclosures

PDF icon Education Council & COI Reviewer Disclosure_090120.pdf

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Kelly Stratton, MD

has a financial relationship (Independent contractor) with Bayer ;.
has a financial relationship (Other) with Oakstone;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Independent contractor) with Integra Life Sciences Services, LLC (LUGPA);.
has a financial relationship (Other) with Astellas Pharma;.
has a financial relationship (Independent contractor) with Integra Life Sciences Services, LLC (LUGPA);.
has a financial relationship (Other) with Astellas Pharma;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Ebix;.
has a financial relationship (Other) with Myovant Sciences;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Ebix;.
has a financial relationship (Other) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Bayer ;.
has a financial relationship (Other) with Oakstone;.
Faculty(s)

Alicia Morgans, MD

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Independent contractor) with Advanced Accelerator Applications;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Advanced Accelerator Applications;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Advanced Accelerator Applications;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Myovant;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Independent contractor) with Advanced Accelerator Applications;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Independent contractor) with Myovant;.

Kelvin Moses, MD, PHD

has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Pfizer;.

Brian Shuch, MD

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Peloton;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Peloton;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.50 hours

Release Date: September, 2020
Expiration Date: September, 2021

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.